Publications by authors named "Bradley Brasher"

Deubiquitylating enzymes (DUBs) counteract ubiquitylation to control stability or activity of substrates. Identification of DUB substrates is challenging because multiple DUBs can act on the same substrate, thwarting genetic approaches. Here, we circumvent redundancy by chemically inhibiting multiple DUBs simultaneously in Xenopus egg extract.

View Article and Find Full Text PDF

We applied a yeast-two-hybrid (Y2H) analysis to screen for ubiquitin variant (UbV) inhibitors of a human deubiquitinase (DUB), ubiquitin-specific protease 2 (USP2). The Y2H screen used USP2 as the bait and a prey library consisting of UbVs randomized at four specific positions, which were known to interact with USP2 from phage display analysis. The screen yielded numerous UbVs that bound to USP2 both as a Y2H interaction in vivo and as purified proteins in vitro.

View Article and Find Full Text PDF
Article Synopsis
  • USP15 is a deubiquitinase that influences various important biological processes and is linked to several diseases.
  • Researchers created specific ubiquitin variants (UbVs) targeting different domains of USP15, including a more effective linear dimer (diUbV) that inhibits USP15’s activity better than single UbVs.
  • These UbVs successfully inhibited the deubiquitination of key substrates and altered USP15's effects on important signaling pathways, paving the way for further research into its role in various health areas like cancer and inflammation.
View Article and Find Full Text PDF

Polyubiquitylation is canonically viewed as a posttranslational modification that governs protein stability or protein-protein interactions, in which distinct polyubiquitin linkages ultimately determine the fate of modified protein(s). We explored whether polyubiquitin chains have any nonprotein-related function. Using in vitro pull-down assays with synthetic materials, we found that polyubiquitin chains with the Lys (K63) linkage bound to DNA through a motif we called the "DNA-interacting patch" (DIP), which is composed of the adjacent residues Thr, Lys, and Glu Upon DNA damage, the binding of K63-linked polyubiquitin chains to DNA enhanced the recruitment of repair factors through their interaction with an Ile patch in ubiquitin to facilitate DNA repair.

View Article and Find Full Text PDF

Activity-based probes (ABPs) are widely used to monitor the activity of enzyme families in biological systems. Inferring enzyme activity from probe reactivity requires that the probe reacts with the enzyme at its active site; however, probe-labeling sites are rarely verified. Here we present an enhanced chemoproteomic approach to evaluate the activity and probe reactivity of deubiquitinase enzymes, using bioorthogonally tagged ABPs and a sequential on-bead digestion protocol to enhance the identification of probe-labeling sites.

View Article and Find Full Text PDF

The ubiquitin system regulates essential cellular processes in eukaryotes. Ubiquitin is ligated to substrate proteins as monomers or chains and the topology of ubiquitin modifications regulates substrate interactions with specific proteins. Thus ubiquitination directs a variety of substrate fates including proteasomal degradation.

View Article and Find Full Text PDF
Article Synopsis
  • EDP-239 is a targeted inhibitor for hepatitis C virus (HCV) NS5A, aimed at treating HCV infection, and has shown potential through both lab and clinical studies.
  • The research focused on identifying mutations in the NS5A gene of HCV genotype 1 that confer resistance to EDP-239, discovering specific resistance-associated mutations (RAMs) in both GT1a and GT1b strains.
  • Mutations present before and after treatment with EDP-239 were linked to reduced effectiveness of the drug, with certain persistent RAMs identified as common in patients over extended treatment periods.
View Article and Find Full Text PDF
Article Synopsis
  • - EDP-239 is an effective hepatitis C virus (HCV) inhibitor that targets a specific protein (NS5A) and works well against various HCV genotypes, showing impressive potency at very low concentrations.
  • - It has been shown to work well alongside other antiviral treatments and remains effective against variants resistant to those treatments, reducing the risk of resistance developing in lab studies.
  • - Clinical trials indicate that EDP-239 can significantly lower HCV virus levels in patients after just a single dose, demonstrating good potential for once-daily treatment.
View Article and Find Full Text PDF

The ubiquitin-modification status of proteins in cells is highly dynamic and maintained by specific ligation machineries (E3 ligases) that tag proteins with ubiquitin or by deubiquitinating enzymes (DUBs) that remove the ubiquitin tag. The development of tools that offset this balance is critical in characterizing signaling pathways that utilize such ubiquitination switches. Herein, we generated a DUB-resistant ubiquitin mutant that is recalcitrant to cleavage by various families of DUBs both in vitro and in mammalian cells.

View Article and Find Full Text PDF

Factor XIII can be activated proteolytically by thrombin cleavage of the activation peptide or non-proteolytically by exposure to 50 mM Ca2+. The resultant transglutaminase cross-links Q and K residues within the noncovalently associated fibrin clot. Hydrogen deuterium exchange coupled with MALDI-TOF MS demonstrated that FXIII activation protects regions within the beta sandwich (98-104) and the beta barrel 1 (526-546) from deuterium, while exposing the potential Q substrate recognition site (220-230) to deuteration (Turner, B.

View Article and Find Full Text PDF

Hedgehog proteins use an auto-processing strategy to generate cholesterol-conjugated peptide products that act as extracellular ligands in a number of developmental signaling pathways. We describe an approach that takes advantage of the hedgehog auto-processing reaction to carry out intracellular modification of heterologous proteins, resulting in their localization to cell membranes. Such processing occurs spontaneously, without accessory proteins or modification by other enzymes.

View Article and Find Full Text PDF

The Abl tyrosine kinase inhibitor STI-571 is effective therapy for stable phase chronic myeloid leukemia (CML) patients, but the majority of CML blast-crisis patients that respond to STI-571 relapse because of reactivation of Bcr-Abl signaling. Mutations of Thr-315 in the Abl kinase domain to Ile (T315I) were previously described in STI-571-resistant patients and likely cause resistance from steric interference with drug binding. Here we identify mutations of Tyr-253 in the nucleotide-binding (P) loop of the Abl kinase domain to Phe or His in patients with advanced CML and acquired STI-571 resistance.

View Article and Find Full Text PDF